Axonics Modulation Technologies Inc (NASDAQ: AXNX), developer of the rechargeable Sacral Neuromodulation (r-SNM) system urinary and bowel dysfunction treatment, declared on Wednesday that it has received Health Canada approval (Homologation d'un instrument medical) to market its External Trial System, an additional element of the Axonics r-SNM system.
The company added that it had previously received Health Canada approval for its miniaturised rechargeable implantable neurostimulator, tined lead, patient and clinician programmers, charger and related accessories. The External Trial System is used to help identify responders to Sacral Neuromodulation therapy prior to a permanent implant. It is composed of a temporary, single-use disposable external stimulator that is connected to either a Tined Lead or a temporary Peripheral Nerve Evaluation (PNE) Lead, depending on the preferred trial method.
Currently, Axonics is conducting a 129-patient pivotal clinical study for urinary incontinence patients under a US FDA Investigational Device Exemption. The enrolment and implant phase was completed in late June 2018 and the company said it expects to file a pre-market approval (PMA) application for FDA approval in the US after the six-month post-implant endpoint has been reached.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study